Long term remission rate for terminal cancers of 92%.
A NOTE ON HOW DATA IS CREATED:
Science measures new treatment results with mathematics to determine if good results can be repeated or were they just a stroke of good luck. Mathematical determination is called ‘statistical analysis.’
Most new chemo therapies aren’t expected to ‘solve’ cancer forever, only to offer a slight improvement over existing therapies. To statistically measure anticipated tiny improvements, sometimes, as little as 2%, you need to collect data on tens of thousands of patient volunteers. Adding a placebo (sugar pill) or the existing drug the trial drug is being compared to, makes it a “double blind” trial.
A double blind trial is conducted by giving the administering doctor two bottles of identical capsules. One bottle is labeled “A,” and the other is labeled “B”. Only one bottle contains the new drug being tested. The doctor divides his volunteers into two groups. Depending on your group you receive only the A or only the B pill throughout the trial. No one knows until the end of the trial who got the drug and who got the placebo.
Just using a placebo means twice the number of people have to participate. It also means, if a sugar pill is used half the group will get no benefit for their time and the inconvenience of being in this trial. Besides the cost drug companies spend to develop the drug, they must also pay thousands of dollars to each university oncologist administering the trial for their time convincing, enrolling, monitoring, and reporting on the patients. When drug companies spend so much money developing and testing a new chemo agent, failure to sell it is untenable. Trials that fail burden other drugs in the company’s “pipeline” with their monetary losses. But trials that show any improvement, even 2%, give the FDA reason to approve the drug, and the company is then free to sell it.
Comparing Toxicity-Free Immuno-Chemotherapy
(which is without side effects, seldom fails, and is effective on multiple types of cancer)
to ordinary chemotherapy
(which fails quite often and is toxic)
just doesn’t take thousands of people.
Like it doesn’t take thousands of people to determine if a square of sweet dark chocolate is preferred over a spoon full of flour-water paste.
CRITERIA FOR THIS DATA SET:
1) Only patients treated directly by the inventor of Toxicity-Free Immuno-Chemotherapy between 2015 and June 2021
2) Patients who were diagnosed as terminal
3) No one was included who left mid-treatment against Calinstit’s advice, consulted with other oncologists, or were convinced they should continue with and received a different treatment after tests indicated Toxicity-Free had put their cancer into remission.
4) The four terminal patients from the 2005-2006 clinical trial for efficacy conducted at the International clinic in Mexico.
RESULTS*
Bladder Patient age 49
Beginning condition: 2014 High grade P3 urothelial cancer. Surgical resection of distal right ureter and re-implantation at Stanford University Hospital. 2015 Recurrence. Recommended to undertake four high dose chemo and undergo bladder excision. Given a prognosis life expectancy of 1 to 2 years.
Started Toxicity-Free treatment September 2015 Ended December 2015.
Cumulative carboplatin AUC 40
Patient remains in remission today. (10 years)
Breast Patient age 45
Beginning condition: January 2017 Mastectomy for 2.6 x .8 x 1.5 mass. Poorly differentiated invasive ductal triple negative cancer.
Started Toxicity-Free treatment May 2017 Ended January 2018. AUC 4 scheduled individually 8 bi-weekly
Cumulative carboplatin AUC 13.6
Patient remains in remission today. (8 years)
Breast Patient age 51
Beginning condition: 2013 underwent lumpectomy, radiotherapy, chemo to address 2 cm mass in right breast. 2017 Triple negative breast 4.5 cm mass in left breast addressed with bilateral mastectomy, chemo. 2019 Brain parietal lobe metastasis addressed with three surgeries, gamma knife radiotherapy, but resulting in no resolution at Canadian Health in Alberta, Canada.
Started Toxicity-Free treatment June 2020 Ended January 2021. bi-weekly treatments
Cumulative carboplatin AUC 21.5
Patient remains in remission today. (5 years)
Breast, Patient age 54
Beginning condition: 2015 – 1.6 cm invasive ductal carcinoma triple negative breast cancer. Oncotype score 63 denoting high recurrence risk.
Started Toxicity-Free treatment June 2020 Ended Nov 2022. 32 bi-weekly AUC (mostly) 4
Cumulative carboplatin AUC 129
Patient remains in remission today. (4 years)
Breast, Patient age 75
Beginning condition: Left invasive ductal ca axillary dissect 2017; received adjuvant (ordinary) chemo for recurrence auxillary and subpectoral lymph node metastasis 2020. Started letrozole, but condition continued to deteriorate. CTC (circulating tumor count) 1 million
Started Toxicity-Free treatment December 2020 with 4 carboplatin AUC 4. CTC reduced to 250,000. Treated low neutrophil issue caused from past adjuvant chemo with filgrastim to stimulate marrow to produce neutrophils.
Cumulative carboplatin AUC 35 over 10 treatments.
Patient failed. Referred to traditional oncologist, to deal with liver metastasis.
Breast, Patient age 38
Beginning condition: 2014, Estrogen/progesterone receptor positive. Mastectomy for 9 cm DCIS high grade, suggestive of poor prognosis (Endo predict score 4.4, Ki 67-20%.)
Started Toxicity-Free treatment September 2016 Ended treatment January 2017. 7 weekly, 4 biweekly treatments.
Cumulative carboplatin AUC 29.9
Patients remains in remission today. (9 years)
NOTE: Conventional treatment recommends all estrogen positive breast cancer patients start estrogen hormone-sensitive suppressive medicines. Most become sterile after these medicines. Those who are not sterile are advised not to become pregnant as high estrogen levels during pregnancy could activate any residual cancer cells. But this patient had a three year old son, and she wanted a daughter. Toxicity-Free treatment does not include hormone suppressants. When she reached remission, Calinstit was confident enough in Toxicity-Free to encourage her to get pregnant. Three years after completing Toxicity-Free she joyfully delivered a beautiful daughter.
Breast Patient age 48
Beginning condition: September 2017 Estrogen/progesterone plus mass. Had mastectomy only while in Canada.
Started Toxicity-Free treatment immediately after mastectomy. 9 bi-weekly carboplatin AUC 3.5, 17 carboplatin AUC ≤ 2.
Cumulative carboplatin AUC 65
Patients remains in remission today. (9 years)
Colon Patient age 53
Beginning condition: Sigmoid colon cancer spread to submucosa, para-aortic lymph node and 3 mm liver lesion.
Started Toxicity-FreeTM treatment March 2019 Ended September 2019. 13 bi-weekly Toxicity-Free treatments averaging AUC 4.
Cumulative carboplatin AUC 52
Patients remains in remission today. (7 years)
NOTE: Conventional chemotherapy cannot eradicate cancer in para-aortic lymph nodes, and they must be surgically removed.
Pancreas Patient 57
Beginning condition: 2016 pancreatic tumor at head of pancreas; with suspicious liver metastasis.
Started Toxicity-Free treatment August 2016 Ended September 2017. 12 bi-weekly AUC 4; 5 bi-weekly AUC 3.
Cumulative carboplatin AUC 63.
Patients remains in remission today. (9 years)
Lung Patient age 85
Beginning condition: Non-small cell, 3.5 x 2.7 cm tumor in right upper lobe. 3.7 x 3.3 cm and 1.2 x 0.7 cm in left lobes.
Started Toxicity-Free treatment July 2018 Ended April 2019. 14 bi-weekly AUC 3. Upper left lobe tumor smaller (2.2 x 1 cm) and second left lobe tumor showing no blood flow April 2023.
Cumulative carboplatin AUC 42
Patients remains in remission today. (7 years)
Breast Patient age 53
Beginning condition: Diagnosed June 2005 lobular carcinoma, Estrogen and progesterone positive. Treated with lumpectomy and auxiliary dissection. Four months later developed a single liver metastasis that was treated with four cycles of capacitabine and paclitaxel without effect.
Started Toxicity-Free carboplatin weekly treatment December 2005 AUC 2. Ultrasound after four treatments showed liver lesion cleared. Underwent four additional Toxicity-FreeTM cycles.
Cumulative carboplatin AUC 16.
Patient remains well and free of cancer 20 years later.
Lung Patient age 61
Beginning condition: Diagnosed with non-small cell stage 3B lung cancer. Received 20 Gy radiotherapy.
Started July 2005 with standard chemo protocol for 2005 era. Comprising of carboplatin with mesna AUC 5 every three weeks, supplemented with gemcitabine on day 1 and 8. Day 8 gemcitabine was omitted with cycle 8. Total of 8 combined cycles of standard protocol with Toxicity-Free mesna added.
Cumulative carboplatin AUC 45.
Patient went into remission and remained so for eight years when he died in an auto accident.
Lung.Patient age 64
Beginning condition: Diagnosed as recurrent non-small cell lung cancer stage 3B. Treated previously, but not in remission.
Started February 2006 with protocol based on standard chemo of 2006. Comprising of carboplatin AUC 5 every three weeks, supplemented with gemcitabine on day 1 and 8. Patient underwent 7 cycles and was granted excused from the eighth because of 500 mile travel from home.
Cumulative carboplatin AUC 35
Patient went into complete remission for three years when he recurred suddenly and died. 2006 life expectancy for non-small cell lung cancer after initial diagnosis was 9 months.
Leukemia, Myelogenous age 61
Beginning condition: Many years history of myeloproliferative disorder which went into acute leukemic phase requiring weekly blood transfusion due to marrow inability to make red cells.
Started Toxicity-Free Chemo in September 2005 with 3 weekly AUC 1.6 carboplatin. Because the patient also suffered from pulmonary hypertension for many years and was taking diuretics, she tended to be dehydrated causing anuria, which can result in retention of carboplatin effectively making carboplatin dose of AUC 1.6 more equivalent to AUC 5 or 6. After three weeks, her neutrophil count was too low to continueToxicity-Free. However, the patient's hemoglobin stabilized without transfusion.
She required no more Toxicity-Free treatments and remained hematologically stable for 18 months at which time she expired due to her pulmonary hypertension.
FAILED PATIENT
The only patient on the list who failed had received extensive conventional chemo that devastated her neutrophils prior to starting Toxicity-Free. Even using neupogen (a bone marrow stimulant, commonly used by oncologists) Calinstit was unable to maintain her neutrophil levels high enough to assist Toxicity-Free in killing her cancer.
ONE OTHER PATIENT OF NOTE
One breast cancer patient age 68 that was not included because she could have survived with conventional (adjuvant) chemotherapy. As a nurse, she chose Toxicity-Free and reached remission after only 9 weekly (2 ½ months) of treatments. She remains in remission today 10 years later.
Breast, Patient age 68
Beginning condition: Estrogen/progesterone, Invasive ductal carcinoma 6 mm + in-situ ductal carcinoma
Started Toxicity-Free treatment June 2016 Ended treatment August 2016 (9 weekly treatments)
Cumulative carboplatin AUC 14.4
Patient remains in remission today. (10 years)
NOTE: Patient avoided a year of toxic chemotherapy and radiation that can leave breasts hypersensitive to the touch for months.
Around 2018, the pink-ribbon originator, Susan G. Komen Foundation website publicized the conclusion of a UK 15 year study published in 2005 Lancet involving twenty-six thousand breast cancer patients. Researchers concluded statistically the benefit gained was 3% greater survival after adjuvant chemotherapy for women aged 61 to 70 who had prior breast surgery.
*The data is as of 2025.